Dimanche, 20 Septembre 2020
Dernières nouvelles
Principale » Q3 2018 EPS Estimates for Hologic, Inc. (HOLX) Raised by Jefferies Group

Q3 2018 EPS Estimates for Hologic, Inc. (HOLX) Raised by Jefferies Group

15 Novembre 2017

Zacks Investment Research cut shares of Hologic from a hold rating to a sell rating in a research report on Wednesday, July 12th. This leaves us with a quarter on quarter earnings per share growth of -31.10%. Leerink Swann reissued a buy rating and set a $46.00 target price on shares of Hologic in a research report on Thursday, July 28th. Jefferies Group also issued estimates for Hologic's Q4 2018 earnings at $0.58 EPS, FY2018 earnings at $2.12 EPS, FY2019 earnings at $2.38 EPS and FY2020 earnings at $2.63 EPS.

Hologic (NASDAQ HOLX) traded down $0.68 during trading hours on Thursday, hitting $38.97. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.49 by $0.01. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The firm had revenue of $802.90 million for the quarter, compared to analysts' expectations of $792.54 million. The firm's quarterly revenue was up 10.5% compared to the same quarter previous year.

Insider Trading Activity for Hologic, Inc. If you are reading this piece on another domain, it was illegally copied and reposted in violation of USA and worldwide trademark & copyright law. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/hologics-holx-buy-rating-reaffirmed-at-piper-jaffray-companies/1771777.html.

A number of other equities analysts have also recently weighed in on HOLX. Goldman Sachs Group, Inc. Finally, Barclays PLC cut their price objective on shares of Hologic from $53.00 to $51.00 and set an "overweight" rating for the company in a report on Thursday, August 3rd.

The average Wall Street analyst rating for Hologic, Inc.is Strong Buy, according to the average of 16 analyst scores. Hologic, Inc. has had 11 insider trades in the last 3 months, including 0 open market buys and 11 sells. Finally, Bank of America Corporation reissued a "neutral" rating and set a $48.00 price objective (up previously from $44.00) on shares of Hologic in a report on Friday, July 21st.

The McDonald's Corp. (MCD) Shares Sold by Ausdal Financial Partners Inc
The fast-food giant reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.01. It fall, as 68 investors sold MCD shares while 616 reduced holdings. 137 funds opened positions while 396 raised stakes.

Among 17 analysts covering Hologic (NASDAQ:HOLX), 12 have Buy rating, 0 Sell and 5 Hold. Stifel Nicolaus upgraded the shares of HOLX in report on Friday, December 11 to "Buy" rating.

The company is so far trading down by 2.41% since yesterday's close of 40.64. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.78. Following the sale, the director now owns 42,898 shares of the company's stock, valued at $1,710,772.24. Columbus Circle Investors purchased a new position in shares of Hologic in the 2nd quarter valued at $54,511,000. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider's stock worth $105,000 after buying an additional 1,535 shares during the last quarter.

As of quarter end AXA had bought a total of 36,264 shares growing its holdings by 10.1%. AXA owns 396,673 shares with a value of $14,554,000. Commonwealth Bank of Australia increased its holdings in Hologic by 31.0% in the second quarter. The sales growth over the last 5 years is at 8.80% while earning per share for the last 12 months is at 2.64. (NASDAQ:HOLX) news were published by: Prnewswire.com which released: "Hologic Announces Financial Results for Fourth Quarter of Fiscal 2017" on November 08, 2017.

Senzar Asset Management Llc decreased Tg Therapeutics Inc (TGTX) stake by 14.97% reported in 2017Q2 SEC filing.

In other news, VP Karleen Marie Oberton sold 1,256 shares of the firm's stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $39.29, for a total value of $49,348.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Lawrence M. Levy sold 9,596 shares of the stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $39.88, for a total transaction of $727,251.68. The disclosure for this sale can be found here. Marshall Wace LLP now owns 525,999 shares of the company's stock valued at $18,200,000 after buying an additional 417,003 shares in the last quarter.